Antivirals for Respiratory Viral Infections: Problems and Prospects

Seminars in Respiratory and Critical Care Medicine

Volumn 37, Issue 4, 2016, Pages 640-646

  Liu, Qiang ^a   Zhou, Yuan Hong ^a   Ye, Feng ^a   Yang, Zhan Qiu ^b  

^a CHINA THREE GORGES UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

antiviral; entry; pathway; replication; respiratory virus

Indexed keywords

ANTIVIRUS AGENT; CELL RECEPTOR; CHINESE DRUG; MEMBRANE PROTEIN; RNA DIRECTED RNA POLYMERASE INHIBITOR; VIRUS RNA;

ANTIGEN DETECTION; ANTIVIRAL ACTIVITY; ARTICLE; BUPLEURUM CHINENSE; CHINESE MEDICINE; COST EFFECTIVENESS ANALYSIS; DRUG DESIGN; ENDOCYTOSIS; FORSYTHIA SUSPENSA; HERB; HUMAN; ISATIS TINCTORIA; LONICERA JAPONICA; MANDARIN; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PROCESSING; SAPOSHNIKOVIA DIVARICATA; SIGNAL TRANSDUCTION; VIRAL ENDOCYTOSIS INHIBITOR; VIRAL RESPIRATORY TRACT INFECTION; VIRUS ASSEMBLY; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS RELEASE; VIRUS REPLICATION; ANIMAL; CORONAVIRUS INFECTION; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; RESPIRATORY TRACT INFECTION; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CORONAVIRUS INFECTIONS; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; RESPIRATORY TRACT INFECTIONS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 84982735786     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0036-1584803     Document Type: Article

References (101)

1. Jartti T., Jartti L., Ruuskanen O., Söderlund-Venermo M. New respiratory viral infections. Curr Opin Pulm Med: 2012; 18 3 271 278
2. Liu Q., Liu D. Y., Yang Z. Q. Characteristics of human infection with avian influenza viruses and development of new antiviral agents. Acta Pharmacol Sin: 2013; 34 10 1257 1269
3. Hirst M., Astell C. R., Griffith M., et al. Novel avian influenza H7N3 strain outbreak, British Columbia. Emerg Infect Dis: 2004; 10 12 2192 2195
4. Peiris M., Yam W. C., Chan K. H., Ghose P., Shortridge K. F. Influenza A H9N2: aspects of laboratory diagnosis. J Clin Microbiol: 1999; 37 10 3426 3427
5. Peiris M., Yuen K. Y., Leung C. W., et al. Human infection with influenza H9N2. Lancet: 1999; 354 9182 916 917
6. Su S., Bi Y., Wong G., Gray G. C., Gao G. F., Li S. Epidemiology, evolution and recent outbreaks of avian influenza viruses in China: A Review. J Virol: 2015; 89 17 8671 8676
7. Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J: 2015; 89 17 8671 8676
8. Osterhaus A. D. New respiratory viruses of humans. Pediatr Infect Dis J: 2008; 27 (10, Suppl): S71 S74
9. Houser K., Subbarao K. Influenza vaccines: challenges and solutions. Cell Host Microbe: 2015; 17 3 295 300
10. Knipe D. M., Howley P. M. Fields virology. 6th ed. Philadelphia, PA Wolters Kluwer/Lippincott Williams & Wilkins Health: 2013
11. Webster R. G., Govorkova E. A. Continuing challenges in influenza. Ann N Y Acad Sci: 2014; 1323 115 139
12. Simões E. A., DeVincenzo J. P., Boeckh M., et al. Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis: 2015; 211 01 S1 S20
13. Zhu J. D., Meng W., Wang X. J., Wang H. C. Broad-spectrum antiviral agents. Front Microbiol: 2015; 6 517
14. Zambon M. C., Stockton J. D., Clewley J. P., Fleming D. M. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet: 2001; 358 9291 1410 1416
15. Henrickson K. J. Advances in the laboratory diagnosis of viral respiratory disease. Pediatr Infect Dis J: 2004; 23 (1, Suppl) S6 S10
16. Principi N., Esposito S. Antigen-based assays for the identification of influenza virus and respiratory syncytial virus: why and how to use them in pediatric practice. Clin Lab Med: 2009; 29 4 649 660
17. Pérez-Ruiz M., Pedrosa-Corral I., Sanbonmatsu-Gámez S., Navarro-Marí M. Laboratory detection of respiratory viruses by automated techniques. Open Virol J: 2012; 6 151 159
18. Dundas N. E., Ziadie M. S., Revell P. A., et al. A lean laboratory: operational simplicity and cost effectiveness of the Luminex xTAG™ respiratory viral panel. J Mol Diagn: 2011; 13 2 175 179
19. Edinger T. O., Pohl M. O., Stertz S. Entry of influenza A virus: host factors and antiviral targets. J Gen Virol: 2014; 95 (Pt 2): 263 277
20. Hedlund M., Aschenbrenner L. M., Jensen K., Larson J. L., Fang F. Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection. J Infect Dis: 2010; 201 7 1007 1015
21. Nicholls J. M., Moss R. B., Haslam S. M. The use of sialidase therapy for respiratory viral infections. Antiviral Res: 2013; 98 3 401 409
22. Moss R. B., Hansen C., Sanders R. L., Hawley S., Li T., Steigbigel R. T. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis: 2012; 206 12 1844 1851
23. Huentelman M. J., Zubcevic J., Hernández Prada J. A., et al. Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor. Hypertension: 2004; 44 6 903 906
24. Danilczyk U., Penninger J. M. Angiotensin-converting enzyme II in the heart and the kidney. Circ Res: 2006; 98 4 463 471
25. Friesen R. H., Koudstaal W., Koldijk M. H., et al. New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS ONE: 2010; 5 2 e9106
26. Lagos R., DeVincenzo J. P., Muñoz A., et al. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children. Pediatr Infect Dis J: 2009; 28 9 835 837
27. Han Y. M., Seo H. J., Choi S. H., et al. Effect of Prophylactic Palivizumab on Admission Due to Respiratory Syncytial Virus Infection in Former Very Low Birth Weight Infants with Bronchopulmonary Dysplasia. J Korean Med Sci: 2015; 30 7 924 931
28. Ramilo O., Lagos R., Sáez-Llorens X., et al. Motavizumab Study Group. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatr Infect Dis J: 2014; 33 7 703 709
29. Hegele R. G. Respiratory syncytial virus therapy and prophylaxis: have we finally turned the corner? Eur Respir J: 2011; 38 2 246 247
30. Plemper R. K. Cell entry of enveloped viruses. Curr Opin Virol: 2011; 1 2 92 100
31. Cosset F. L., Lavillette D. Cell entry of enveloped viruses. Adv Genet: 2011; 73 121 183
32. Teissier E., Penin F., Pécheur E. I. Targeting cell entry of enveloped viruses as an antiviral strategy. Molecules: 2011; 16 1 221 250
33. de Vries E., Tscherne D. M., Wienholts M. J., et al. Dissection of the influenza A virus endocytic routes reveals macropinocytosis as an alternative entry pathway. PLoS Pathog: 2011; 7 3 e1001329
34. Sun X., Whittaker G. R. Role of the actin cytoskeleton during influenza virus internalization into polarized epithelial cells. Cell Microbiol: 2007; 9 7 1672 1682
35. Ehrhardt C., Marjuki H., Wolff T., et al. Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during influenza virus infection and host cell defence. Cell Microbiol: 2006; 8 8 1336 1348
36. Eierhoff T., Hrincius E. R., Rescher U., Ludwig S., Ehrhardt C. The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells. PLoS Pathog: 2010; 6 9 e1001099
37. Li S., Sieben C., Ludwig K., et al. pH-Controlled two-step uncoating of influenza virus. Biophys J: 2014; 106 7 1447 1456
38. Garcia N. K., Guttman M., Ebner J. L., Lee K. K. Dynamic changes during acid-induced activation of influenza hemagglutinin. Structure: 2015; 23 4 665 676
39. Ochiai H., Sakai S., Hirabayashi T., Shimizu Y., Terasawa K. Inhibitory effect of bafilomycin A1, a specific inhibitor of vacuolar-type proton pump, on the growth of influenza A and B viruses in MDCK cells. Antiviral Res: 1995; 27 4 425 430
40. Chen H. W., Cheng J. X., Liu M. T., et al. Inhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses. Antiviral Res: 2013; 99 3 371 382
41. Müller K. H., Kainov D. E., El Bakkouri K., et al. The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections. Br J Pharmacol: 2011; 164 2 344 357
42. Vigant F., Lee J., Hollmann A., et al. A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion. PLoS Pathog: 2013; 9 4 e1003297
43. Wolf M. C., Freiberg A. N., Zhang T., et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A: 2010; 107 7 3157 3162
44. Leneva I. A., Russell R. J., Boriskin Y. S., Hay A. J. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res: 2009; 81 2 132 140
45. Boriskin Y. S., Leneva I. A., Pécheur E. I., Polyak S. J. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem: 2008; 15 10 997 1005
46. Burtseva E. I., Shevchenko E. S., Beliakova N. V., et al. [Monitoring of the sensitivity of epidemic influenza virus strains isolated in Russia to etiotropic chemical agents]. Vopr Virusol: 2009; 54 5 24 28
47. DeVincenzo J. P., Whitley R. J., Mackman R. L., et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med: 2014; 371 8 711 722
48. Douglas J. L., Panis M. L., Ho E., et al. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob Agents Chemother: 2005; 49 6 2460 2466
49. Elshabrawy H. A., Fan J., Haddad C. S., et al. Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay. J Virol: 2014; 88 8 4353 4365
50. Gu R., Liu L. A., Wei D. Drug inhibition and proton conduction mechanisms of the influenza a M2 proton channel. Adv Exp Med Biol: 2015; 827 205 226
51. Wei C., Pohorille A. M2 proton channel: toward a model of a primitive proton pump. Orig Life Evol Biosph: 2015; 45 1-2 241 248
52. Ilyushina N. A., Govorkova E. A., Webster R. G. Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia. Virology: 2005; 341 1 102 106
53. Huang Y., Hu B., Wen X., et al. Evolution analysis of the matrix (M) protein genes of 17 H9N2 chicken influenza viruses isolated in northern China during 1998-2008. Virus Genes: 2009; 38 3 398 403
54. Centers for Disease Control and Prevention (CDC) Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep: 2009; 58 16 433 435
55. Wang J., Ma C., Wang J., et al. Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus. J Med Chem: 2013; 56 7 2804 2812
56. Rodriguez-Frandsen A., Alfonso R., Nieto A. Influenza virus polymerase: Functions on host range, inhibition of cellular response to infection and pathogenicity. Virus Res: 2015; 209 23 38
57. Furuta Y., Gowen B. B., Takahashi K., Shiraki K., Smee D. F., Barnard D. L. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res: 2013; 100 2 446 454
58. Nagata T., Lefor A. K., Hasegawa M., Ishii M. Favipiravir: a new medication for the Ebola virus disease pandemic. Disaster Med Public Health Prep: 2015; 9 1 79 81
59. Kiso M., Takahashi K., Sakai-Tagawa Y., et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci U S A: 2010; 107 2 882 887
60. Yamada K., Koyama H., Hagiwara K., et al. Identification of a novel compound with antiviral activity against influenza A virus depending on PA subunit of viral RNA polymerase. Microbes Infect: 2012; 14 9 740 747
61. Warren T. K., Wells J., Panchal R. G., et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature: 2014; 508 7496 402 405
62. Wang G., Deval J., Hong J., et al. Discovery of 4′-chloromethyl-2′-deoxy-3′,5′-di-O-isobutyryl-2′-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J Med Chem: 2015; 58 4 1862 1878
63. Krumm S. A., Ndungu J. M., Yoon J. J., et al. Potent host-directed small-molecule inhibitors of myxovirus RNA-dependent RNA-polymerases. PLoS ONE: 2011; 6 5 e20069
64. Brochot E., François C., Castelain S., et al. A new tool to study ribavirin-induced haemolysis. Antivir Ther: 2012; 17 7 1311 1317
65. Sidwell R. W., Bailey K. W., Wong M. H., Barnard D. L., Smee D. F. In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res: 2005; 68 1 10 17
66. Ilyushina N. A., Hay A., Yilmaz N., Boon A. C., Webster R. G., Govorkova E. A. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother: 2008; 52 11 3889 3897
67. Smith C. B., Charette R. P., Fox J. P., Cooney M. K., Hall C. E. Lack of effect of oral ribavirin in naturally occurring influenza A virus (H1N1) infection. J Infect Dis: 1980; 141 5 548 554
68. Gish R. G. Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother: 2006; 57 1 8 13
69. Evans D. R., Guy H. I. Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. J Biol Chem: 2004; 279 32 33035 33038
70. Hoffmann H. H., Kunz A., Simon V. A., Palese P., Shaw M. L. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci U S A: 2011; 108 14 5777 5782
71. Smee D. F., Hurst B. L., Day C. W. D282, a non-nucleoside inhibitor of influenza virus infection that interferes with de novo pyrimidine biosynthesis. Antivir Chem Chemother: 2012; 22 6 263 272
72. Graham A. C., Temple R. M., Obar J. J. Mast cells and influenza a virus: association with allergic responses and beyond. Front Immunol: 2015; 6 238
73. Frieman M., Basu D., Matthews K., et al. Yeast based small molecule screen for inhibitors of SARS-CoV. PLoS ONE: 2011; 6 12 e28479
74. Adedeji A. O., Sarafianos S. G. Antiviral drugs specific for coronaviruses in preclinical development. Curr Opin Virol: 2014; 8 45 53
75. Valiente-Echeverría F., Hermoso M. A., Soto-Rifo R. RNA helicase DDX3: at the crossroad of viral replication and antiviral immunity. Rev Med Virol: 2015; 25 5 286 299
76. Tanner J. A., Zheng B. J., Zhou J., et al. The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. Chem Biol: 2005; 12 3 303 311
77. Adedeji A. O., Singh K., Kassim A., et al. Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses. Antimicrob Agents Chemother: 2014; 58 8 4894 4898
78. Liu G., Xiang Y., Guo C., Pei Y., Wang Y., Kitazato K. Cofilin-1 is involved in regulation of actin reorganization during influenza A virus assembly and budding. Biochem Biophys Res Commun: 2014; 453 4 821 825
79. Rossman J. S., Lamb R. A. Influenza virus assembly and budding. Virology: 2011; 411 2 229 236
80. Chase G. P., Rameix-Welti M. A., Zvirbliene A., et al. Influenza virus ribonucleoprotein complexes gain preferential access to cellular export machinery through chromatin targeting. PLoS Pathog: 2011; 7 9 e1002187
81. Perwitasari O., Johnson S., Yan X., et al. Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo. J Virol: 2014; 88 17 10228 10243
82. Rossignol J. F., La Frazia S., Chiappa L., Ciucci A., Santoro M. G. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem: 2009; 284 43 29798 29808
83. Rossignol J. F. Thiazolides: a new class of antiviral drugs. Expert Opin Drug Metab Toxicol: 2009; 5 6 667 674
84. de Wilde A. H., Li Y., van der Meer Y., et al. Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis. J Virol: 2013; 87 3 1454 1464
85. Hamamoto I., Harazaki K., Inase N., Takaku H., Tashiro M., Yamamoto N. Cyclosporin A inhibits the propagation of influenza virus by interfering with a late event in the virus life cycle. Jpn J Infect Dis: 2013; 66 4 276 283
86. Gasparini R., Amicizia D., Lai P. L., Bragazzi N. L., Panatto D. Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus. J Prev Med Hyg: 2014; 55 4 109 129
87. Varghese J. N., Smith P. W., Sollis S. L., et al. Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure: 1998; 6 6 735 746
88. Yamashita M., Tomozawa T., Kakuta M., Tokumitsu A., Nasu H., Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother: 2009; 53 1 186 192
89. Dharan N. J., Gubareva L. V., Meyer J. J., et al. Oseltamivir-Resistance Working Group. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA: 2009; 301 10 1034 1041
90. Planz O. Development of cellular signaling pathway inhibitors as new antivirals against influenza. Antiviral Res: 2013; 98 3 457 468
91. Ludwig S. Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. J Antimicrob Chemother: 2009; 64 1 1 4
92. Droebner K., Pleschka S., Ludwig S., Planz O. Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo. Antiviral Res: 2011; 92 2 195 203
93. Mazur I., Wurzer W. J., Ehrhardt C., et al. Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity. Cell Microbiol: 2007; 9 7 1683 1694
94. Guidelines for Management of Avian H7N9 Influenza Infection. 2013; http://www.moh.gov.cn/ewebeditor/uploadfile/2013/04/20130410212136993.doc
95. Guidelines for Management of Pandemic (H1N1) 2009 Influenza. 2009; http://www.moh.gov.cn/mohwsyjbgs/s9990/200910/43111.shtml
96. Shang X., Pan H., Li M., Miao X., Ding H. Lonicera japonica Thunb.: ethnopharmacology, phytochemistry and pharmacology of an important traditional Chinese medicine. J Ethnopharmacol: 2011; 138 1 1 21
97. WHO monographs on selected medicinal plants. 1999; http://apps.who.int/medicinedocs/en/d/Js2200e/
98. Li C., Dai Y., Zhang S. X., et al. Quinoid glycosides from Forsythia suspensa. Phytochemistry: 2014; 104 105 113
99. Xu J. J., Wu X., Li M. M., et al. Antiviral activity of polymethoxylated flavones from Guangchenpi, the edible and medicinal pericarps of citrus reticulata 'Chachi' J Agric Food Chem: 2014; 62 10 2182 2189
100. Liu Q., Lu L., Hua M., et al. Jiawei-Yupingfeng-Tang, a Chinese herbal formula, inhibits respiratory viral infections in vitro and in vivo. J Ethnopharmacol: 2013; 150 2 521 528
101. Ling J. X., Wei F., Li N., et al. Amelioration of influenza virus-induced reactive oxygen species formation by epigallocatechin gallate derived from green tea. Acta Pharmacol Sin: 2012; 33 12 1533 1541